Compare FirstEnergy Corp. (FE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs BIO-TECHNE Corp — how do they compare? FirstEnergy Corp. trades at $49.2 (market cap $28.13B), while BIO-TECHNE Corp trades at $71.57 (market cap $11.14B). The key difference: FirstEnergy Corp. is far larger — about 2.5× BIO-TECHNE Corp's market cap, and FirstEnergy Corp. pays the higher dividend (3.82%). Which is the better fit depends on your goals.
| FE | TECH | |
|---|---|---|
Market Cap | $28.13B | $11.14B |
Sector | Utilities | Health |
52-Week High | $51.91 | $71.48 |
52-Week Low | $40.30 | $43.31 |
Enterprise Value | $56.14B | $11.22B |
Dividend Yield | 3.82% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $49.22, up 1.63% with a bullish technical signal. The stock shows consistent revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, supported by strong cash flow from operations of $3.70B. Recent news highlights growth from data center demand and a $36B investment plan.
Outlook remains positive due to strategic investments and rising energy demand, but risks include high debt levels and regulatory pressures. The stock offers steady growth potential with a dividend yield, though investors should monitor execution of capital expenditures and interest rate impacts on financing costs.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
